LT3841120T - Antikūnai, surišantys citrulinuotą histoną 2a ir (arba) 4 - Google Patents
Antikūnai, surišantys citrulinuotą histoną 2a ir (arba) 4Info
- Publication number
- LT3841120T LT3841120T LTEPPCT/EP2019/072302T LTEP2019072302T LT3841120T LT 3841120 T LT3841120 T LT 3841120T LT EP2019072302 T LTEP2019072302 T LT EP2019072302T LT 3841120 T LT3841120 T LT 3841120T
- Authority
- LT
- Lithuania
- Prior art keywords
- histeine
- citrulated
- antibodies binding
- antibodies
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813597.0A GB201813597D0 (en) | 2018-08-21 | 2018-08-21 | Antibody |
| GBGB1900983.6A GB201900983D0 (en) | 2019-01-24 | 2019-01-24 | Antibody |
| PCT/EP2019/072302 WO2020038963A1 (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3841120T true LT3841120T (lt) | 2025-11-10 |
Family
ID=67688785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2019/072302T LT3841120T (lt) | 2018-08-21 | 2019-08-20 | Antikūnai, surišantys citrulinuotą histoną 2a ir (arba) 4 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20210395350A1 (enExample) |
| EP (2) | EP4659807A3 (enExample) |
| JP (2) | JP7434328B2 (enExample) |
| KR (2) | KR20250148711A (enExample) |
| CN (2) | CN112930356B (enExample) |
| AU (3) | AU2019326740B2 (enExample) |
| CA (1) | CA3110013A1 (enExample) |
| DK (1) | DK3841120T3 (enExample) |
| ES (1) | ES3048210T3 (enExample) |
| FI (1) | FI3841120T3 (enExample) |
| HR (1) | HRP20251346T1 (enExample) |
| IL (2) | IL322482A (enExample) |
| LT (1) | LT3841120T (enExample) |
| MX (3) | MX2025007881A (enExample) |
| PT (1) | PT3841120T (enExample) |
| RS (1) | RS67385B1 (enExample) |
| SG (1) | SG11202101652PA (enExample) |
| SI (1) | SI3841120T1 (enExample) |
| SM (1) | SMT202500388T1 (enExample) |
| WO (1) | WO2020038963A1 (enExample) |
| ZA (1) | ZA202101051B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| US10940204B2 (en) | 2015-07-31 | 2021-03-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| LT3841120T (lt) | 2018-08-21 | 2025-11-10 | Antikūnai, surišantys citrulinuotą histoną 2a ir (arba) 4 | |
| JP2022504139A (ja) | 2018-10-05 | 2022-01-13 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルムの除去のためのｈｍｇｂ１タンパク質誘導体 |
| WO2021209465A1 (en) * | 2020-04-14 | 2021-10-21 | Universiteit Maastricht | Peptide for the treatment of net-associated diseases |
| US20230272054A1 (en) * | 2020-07-07 | 2023-08-31 | Research Institute At Nationwide Children's Hospital | Combination therapies for the treatment and prevention of biofilms |
| GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
| EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
| IL308223A (en) * | 2021-05-04 | 2024-01-01 | Citryll B V | Inhibition of eosinophilic traps |
| EP4442705A1 (en) | 2023-04-03 | 2024-10-09 | Citryll B.V. | Dosage |
| GB202318703D0 (en) | 2023-12-07 | 2024-01-24 | Citryll B V | Diagnostic agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| EP2294086B1 (en) * | 2008-06-04 | 2017-09-13 | ModiQuest B.V. | Anti-inflammatory agents |
| US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
| EP2332987A1 (en) | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
| GB201410520D0 (en) * | 2014-06-12 | 2014-07-30 | Univ London Queen Mary | Antibody |
| ES2724364T3 (es) * | 2014-12-11 | 2019-09-10 | Modiquest B V | Procedimiento de tratamiento de fibrosis pulmonar idiopática |
| WO2017021552A1 (en) | 2015-08-06 | 2017-02-09 | Novimmune Sa | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| LT3841120T (lt) | 2018-08-21 | 2025-11-10 | Antikūnai, surišantys citrulinuotą histoną 2a ir (arba) 4 | |
| IL308223A (en) | 2021-05-04 | 2024-01-01 | Citryll B V | Inhibition of eosinophilic traps |
| CN117396221A (zh) * | 2021-05-04 | 2024-01-12 | 奇特里尔私人有限公司 | 嗜酸性粒细胞陷阱的抑制 |
-
2019
- 2019-08-20 LT LTEPPCT/EP2019/072302T patent/LT3841120T/lt unknown
- 2019-08-20 HR HRP20251346TT patent/HRP20251346T1/hr unknown
- 2019-08-20 AU AU2019326740A patent/AU2019326740B2/en active Active
- 2019-08-20 SI SI201930975T patent/SI3841120T1/sl unknown
- 2019-08-20 MX MX2025007881A patent/MX2025007881A/es unknown
- 2019-08-20 SM SM20250388T patent/SMT202500388T1/it unknown
- 2019-08-20 MX MX2021001902A patent/MX2021001902A/es unknown
- 2019-08-20 RS RS20251114A patent/RS67385B1/sr unknown
- 2019-08-20 KR KR1020257029356A patent/KR20250148711A/ko active Pending
- 2019-08-20 EP EP25196231.2A patent/EP4659807A3/en active Pending
- 2019-08-20 ES ES19756180T patent/ES3048210T3/es active Active
- 2019-08-20 EP EP19756180.6A patent/EP3841120B1/en active Active
- 2019-08-20 KR KR1020217008362A patent/KR102871821B1/ko active Active
- 2019-08-20 CN CN201980070130.3A patent/CN112930356B/zh active Active
- 2019-08-20 IL IL322482A patent/IL322482A/en unknown
- 2019-08-20 PT PT197561806T patent/PT3841120T/pt unknown
- 2019-08-20 SG SG11202101652PA patent/SG11202101652PA/en unknown
- 2019-08-20 JP JP2021534820A patent/JP7434328B2/ja active Active
- 2019-08-20 DK DK19756180.6T patent/DK3841120T3/da active
- 2019-08-20 FI FIEP19756180.6T patent/FI3841120T3/fi active
- 2019-08-20 US US17/269,509 patent/US20210395350A1/en not_active Abandoned
- 2019-08-20 CN CN202510240710.XA patent/CN120058926A/zh active Pending
- 2019-08-20 WO PCT/EP2019/072302 patent/WO2020038963A1/en not_active Ceased
- 2019-08-20 CA CA3110013A patent/CA3110013A1/en active Pending
- 2019-08-20 IL IL280995A patent/IL280995B2/en unknown
-
2021
- 2021-02-16 ZA ZA2021/01051A patent/ZA202101051B/en unknown
- 2021-02-17 MX MX2025007882A patent/MX2025007882A/es unknown
- 2021-07-06 US US17/368,720 patent/US11345750B2/en active Active
-
2022
- 2022-05-27 US US17/827,488 patent/US12590143B2/en active Active
-
2024
- 2024-02-06 JP JP2024016700A patent/JP7835788B2/ja active Active
-
2026
- 2026-02-20 AU AU2026201303A patent/AU2026201303A1/en active Pending
- 2026-02-20 AU AU2026201302A patent/AU2026201302A1/en active Pending
- 2026-03-05 US US19/558,405 patent/US20260176342A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| SG11202007074PA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| ZA202103061B (en) | Anti-cldn18.2 antibody and uses thereof | |
| IL277072A (en) | Anti-claudin antibodies 18.2 | |
| ZA202106880B (en) | Anti-claudin 18.2 antibody and application thereof | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| EP3878863A4 (en) | ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE | |
| IL278924A (en) | Antibodies specific to GUCY2C and their uses | |
| EP4017883A4 (en) | Novel anti-cldn18.2 antibodies | |
| EP3992209A4 (en) | CLDN18.2 ANTIBODIES AND USE THEREOF | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| IL291299A (en) | Anti-TNFR2 antibodies, preparations containing them and their uses | |
| IL279355A (en) | Anti-steap1 antigen-binding protein | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| LT3247725T (lt) | Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123 | |
| SG11202104240TA (en) | Cll1-targeting antibody and application thereof | |
| IL285626A (en) | Claudin 6 antibodies and uses thereof | |
| SG11202106717PA (en) | Antibodies recognizing tau | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof |